Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma
To explore the efficacy of Tislelizumab combined with chemotherapy in the treatment of locally unresectable esophageal squamous cell carcinoma (ESCC)
Immunotherapy Esophagus Cancer
DRUG: Tislelizumab|DRUG: Albumin paclitaxel|DRUG: Nedaplatin|RADIATION: radiotherapy
progression free survival, Time from enrollment to the onset of disease progression or death, up to 24 months
Objective Response Rate (ORR), Objective Response Rate Determine the tumor shrinkage rate, tumor boundary and the adhesion of tumor, every 6 weeks （up to 24 months）|Overall survival (OS), Defined from date of Signing ICF to date of first documentation of death from any cause or censored at the date of the last follow-up., every 3 months (up to 24 months)
To explore the efficacy of Tislelizumab combined with chemotherapy in the treatment of locally unresectable esophageal squamous cell carcinoma (ESCC)